Benchmark Lowers Danaher (NYSE:DHR) Price Target to $325.00

Danaher (NYSE:DHRGet Rating) had its price target cut by Benchmark from $345.00 to $325.00 in a research report released on Tuesday, The Fly reports. They currently have a buy rating on the conglomerate’s stock.

Several other equities analysts have also recently commented on DHR. Royal Bank of Canada raised their price target on shares of Danaher from $317.00 to $318.00 and gave the company an outperform rating in a research report on Friday, September 16th. Robert W. Baird boosted their price objective on shares of Danaher from $319.00 to $325.00 in a report on Friday, July 22nd. Barclays boosted their price objective on shares of Danaher from $290.00 to $310.00 in a research report on Friday, July 22nd. StockNews.com raised shares of Danaher from a buy rating to a strong-buy rating in a research report on Friday, August 26th. Finally, UBS Group upped their target price on shares of Danaher from $297.00 to $323.00 and gave the company a buy rating in a research note on Thursday, July 28th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Danaher presently has an average rating of Buy and an average price target of $321.75.

Danaher Price Performance

Shares of DHR opened at $274.37 on Tuesday. The firm has a market capitalization of $199.59 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 1.33 and a beta of 0.88. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.75 and a quick ratio of 1.32. Danaher has a 1-year low of $233.71 and a 1-year high of $331.68. The company’s fifty day moving average price is $279.85 and its 200-day moving average price is $269.86.

Danaher (NYSE:DHRGet Rating) last released its quarterly earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share for the quarter, topping the consensus estimate of $2.35 by $0.41. The firm had revenue of $7.75 billion during the quarter, compared to the consensus estimate of $7.29 billion. Danaher had a net margin of 20.61% and a return on equity of 18.57%. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. On average, equities research analysts predict that Danaher will post 10.4 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 0.36%. The ex-dividend date of this dividend is Thursday, September 29th. Danaher’s dividend payout ratio (DPR) is currently 11.78%.

Insider Transactions at Danaher

In related news, CEO Rainer Blair sold 25,000 shares of the firm’s stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $300.00, for a total value of $7,500,000.00. Following the sale, the chief executive officer now directly owns 79,739 shares of the company’s stock, valued at $23,921,700. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Rainer Blair sold 25,000 shares of Danaher stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $300.00, for a total transaction of $7,500,000.00. Following the sale, the chief executive officer now directly owns 79,739 shares of the company’s stock, valued at $23,921,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joakim Weidemanis sold 12,000 shares of Danaher stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $271.13, for a total value of $3,253,560.00. Following the sale, the executive vice president now directly owns 74,398 shares in the company, valued at $20,171,529.74. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,906 shares of company stock valued at $11,823,179. 11.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Danaher

A number of hedge funds have recently made changes to their positions in the stock. US Asset Management LLC raised its position in shares of Danaher by 0.6% during the first quarter. US Asset Management LLC now owns 5,774 shares of the conglomerate’s stock worth $1,694,000 after acquiring an additional 37 shares during the last quarter. Advisor OS LLC increased its holdings in Danaher by 0.6% in the second quarter. Advisor OS LLC now owns 6,253 shares of the conglomerate’s stock worth $1,585,000 after purchasing an additional 37 shares in the last quarter. Mairs & Power Inc. increased its holdings in Danaher by 4.1% in the fourth quarter. Mairs & Power Inc. now owns 959 shares of the conglomerate’s stock worth $316,000 after purchasing an additional 38 shares in the last quarter. Strengthening Families & Communities LLC grew its stake in Danaher by 3.2% in the second quarter. Strengthening Families & Communities LLC now owns 1,248 shares of the conglomerate’s stock valued at $364,000 after acquiring an additional 39 shares during the period. Finally, Mutual Advisors LLC grew its stake in Danaher by 0.7% in the fourth quarter. Mutual Advisors LLC now owns 5,792 shares of the conglomerate’s stock valued at $1,906,000 after acquiring an additional 40 shares during the period. 77.27% of the stock is currently owned by institutional investors.

About Danaher

(Get Rating)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.

Featured Articles

The Fly logo

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.